Floatz logo

5-azacytidine

Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type

National Cancer Institute (NCI)Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 2CCC
Golcadomide
Mayo Clinic
Phase 2CCC
cc-5013
National Cancer Institute (NCI)
Phase 2CCC
Ibrutinib
National Cancer Institute (NCI)
Phase 2CCC
Venetoclax
National Cancer Institute (NCI)
Phase 2CCC

View all 9 →

Same molecule, other indications

5-azacytidine is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BB
Indicative ·
70 / 100
View asset →
Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic LeukemiaDormant
BB
Indicative ·
65 / 100
View asset →
myelodysplastic syndromeDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →